Results 171 to 180 of about 10,168 (235)

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

Advanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang, Yu‐Chuan Lin, Chih‐Ming Pan, Yeh Chen, Ming‐You Shie, Cheng‐Yu Chen, Kai‐Wen Kan, Yi‐Wen Chen, Ming‐Chao Liu, Chung‐Chun Wu, Yu‐Ting Chiang, Huai‐Ping Ho, Chen‐Yu Lin, Pei‐Ying Lin, Yu‐Han Huang, Steffany Rusli, Wan‐Yu Mao, Pei‐Wen Huang, Sin‐Ting Wang, Wan‐Chen Tsai, Ya‐Hsu Chiu, Ting‐Hsun Lin, Wan‐Ling Chiang, Che‐Kai Chang, Zi‐Lun Lai, Mei‐Chih Chen, Shao‐Chih Chiu, Der‐Yang Cho   +27 more
wiley   +1 more source

Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. [PDF]

J Thorac Dis, 2018
Katoh M.
europepmc   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source

Mechanism and reversal strategies of immune checkpoint blockers drug resistance

Precision Medicine Research, 2019
openaire   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

Advanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Afsana Parveen Jahir Hussain, Sivasubramani Narayanan, Sabir Salim, Loganayaki Periyasamy, Natarajan Aravindan   +7 more
wiley   +1 more source

Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma

Advanced Science, EarlyView.
CSPG4 is identified as a high‐value, stemness‐associated target in HPV‐negative HNSCC. By implementing rational biophysical engineering, a humanized and charge‐optimized CAR is developed to overcome tonic signaling‐induced exhaustion. This strategy induces a profound transcriptomic shift toward a rejuvenated, stem‐like memory state, significantly ...
Xiang Xu, Shizhen Qiu, Zhitong Wang, Dan Li, Min Chen, Yinying Chu, Guangfei Li, Yi Fang, Changjiang Li, Fang Shi, Peijie He, Haitao Wu, Haopeng Wang, Jian Chen   +13 more
wiley   +1 more source

Novel applications for immune checkpoint blockers in head and neck cancer

Durvalumab has shown activity in squamous cell carcinoma of the head and neck. Locally advanced resectable cancers of this type represent a challenge, as the majority of these patients still die from this disease in spite of surgery, radio- and chemotherapy.
openaire   +1 more source

DADA Enhances CD8+ T Cell Stemness to Improve Anti‐Tumor Immunity and Immunotherapy Efficacy

Advanced Science, EarlyView.
Diisopropylamine dichloroacetate (DADA) enhances CD8+ T cell stemness by improving OXPHOS and mitochondrial fitness in a PDK1‐depenpendent manner. This metabolic shift strengthens CD8+ T cell anti‐tumor immunity, improves responses to PD‐1 blockade, and endows CAR‐T cells with prolonged persistence and resistance to terminal exhaustion, highlighting a ...
Mingyue Bi, Fei Li, Heng Jiang, Lingling Gu, Mengjie Sun, Kunyu Lu, Pianpian Liu, Ruyue Xie, Wenqiang Ma, Meijuan Zheng, Xianwei Wang, Xuefu Wang, Jingjing Cong   +12 more
wiley   +1 more source

ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion

Advanced Science, EarlyView.
ZBTB21 is a transcription factor that epigenetically suppresses pyroptosis and MHC‐I antigen presentation, enabling tumor immune evasion. Genetic ablation of ZBTB21 activates pyroptotic cell death and enhances antigen presentation, recruiting CD8+ T cells to overcome immune checkpoint blockade resistance.
Lei Zhao, Linlin Sheng, Jianhao Qiu, Junjie Ma, Kai Jin, Binggong Zhao, Tianrun Miao, Jing Chen, Yehong Li, Zhan Zhang, Dongfeng Sun, Yongmeng Li, Hui Tian   +12 more
wiley   +1 more source

Multi‐Organelle Stress‐Induced Paraptosis by a ROS‐Amplifying Nanocatalyst for Enhanced Cancer Immunotherapy

Advanced Science, EarlyView.
The engineered TF‐Fe@LC nanoplatform programs paraptotic death via multipath ROS amplification that disrupts redox homeostasis, provoking mitochondrial dysfunction, autophagic blockade, and ER stress. This caspase‐independent process elicits robust immunogenic cell death, combining with αPD‐L1 to activate systemic CD8+ T‐cell immunity and suppress ...
Zhe Yu, Haozhe Ren, Hua Li, Jinghan Zhao, Miaomiao Cao, Tian Tang, Youbei Qiao, Liting Chen, Tiehong Yang, Hong Wu   +9 more
wiley   +1 more source